United Therapeutics Corporation v. Liquidia Technologies, Inc.
| United Therapeutics Corporation |
| Liquidia Technologies, Inc. |
| LGM Pharma, LLC |
| 1:2021mc00325 |
| August 18, 2021 |
| U.S. District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 15, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 20 REDACTED VERSION of #19 Letter, by Liquidia Technologies, Inc.. (Hoeschen, Nathan) Modified on 10/15/2021 (nms). |
| Remark: Docketing Clerk filed the joint letter at D.I. 19 on behalf of counsel. It was previously docketed in the wrong case. (ceg) |
| Filing 19 [SEALED] Joint Letter to Hon. Jennifer L. Hall from Nathan Hoeschen regarding the Subpoenas Served on Dr. Roscigno. (ceg) |
| Filing 18 REDACTED VERSION of #13 Letter, by United Therapeutics Corporation. (Flynn, Michael) Modified on 10/5/2021 (nms). |
Filing 17
ORAL ORDER: The redacted filings (D.I. #16 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 9/28/2021. (nms)
|
| Filing 16 REDACTED VERSION of #13 Letter, by United Therapeutics Corporation. (Flynn, Michael) Modified on 9/28/2021 (nms). |
| Filing 15 REDACTED VERSION of #12 Letter, by LGM Pharma, LLC, Liquidia Technologies, Inc.. (Hoeschen, Nathan) Modified on 9/24/2021 (nms). |
|
Filing 14
ORAL ORDER: For the reasons stated in open court on September 22, 2021, the Joint Motion for Teleconference to Resolve Discovery Dispute (C.A. No. 20-755, D.I. 170) and Non-Party LGM Pharma's Motion to Quash Subpoenas (C.A. No. 21-325, D.I. 1) are GRANTED IN PART and DENIED IN PART. The transcript of the September 22, 2021 combined discovery dispute teleconference shall serve as the Order of the Court. ORDERED by Judge Jennifer L. Hall on 9/23/2021. Associated Cases: 1:20-cv-00755-RGA-JLH, 1:21-mc-00325-RGA(ceg)
|
| Minute Entry for proceedings held before Judge Jennifer L. Hall - Combined Discovery Dispute Teleconference held on 9/22/2021 re Joint Motion for Teleconference to Resolve Discovery Dispute (C.A. No. 20-755, D.I. 170) and Non-Party LGM Pharmas Motion to Quash Subpoenas (C.A. No. 21-325, D.I. 1). (*Court Reporter Jennifer Guy.) Associated Cases: 1:20-cv-00755-RGA-JLH, 1:21-mc-00325-RGA(ceg) |
| Filing 13 [SEALED] Letter to The Honorable Jennifer L. Hall, from Michael Flynn, regarding response to LGM Pharma, LLC's Motion to Quash Letter (D.I. 12). (Attachments: #1 Exhibits A-E)(Flynn, Michael) Modified on 9/21/2021 (nms). |
| Filing 12 [SEALED] Letter to The Honorable Jennifer L. Hall from Nathan R. Hoeschen regarding Non-Party LGM Pharma, LLC's Motion to Quash. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5)(Hoeschen, Nathan) |
|
Filing 11
ORAL ORDER Setting Teleconference: Pending before the Court are the Joint Motion for Teleconference to Resolve Discovery Dispute (C.A. No. 20-755, D.I. 170) and Non-Party LGM Pharmas Motion to Quash Subpoenas (C.A. No. 21-325, D.I. 1). A combined discovery dispute teleconference is scheduled for September 22, 2021 at 2:00 PM Eastern Time before Judge Jennifer L. Hall. Briefing on the Motion to Quash shall occur in accordance with Judge Hall's standard discovery dispute procedures; the Court will not consider briefs previously filed. By no later than September 16, 2021, each party seeking relief in each dispute shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than September 20, 2021, any parties opposing each application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: [email protected]. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 9/13/2021. Associated Cases: 1:20-cv-00755-RGA-JLH, 1:21-mc-00325-RGA(ceg)
|
| Filing 10 NOTICE of Appearance by Michael J. Flynn on behalf of United Therapeutics Corporation (Flynn, Michael) |
|
Filing 9
ORAL ORDER: The Motion to Quash Subpoena (D.I. #1 ) is now REFERRED to Magistrate Judge Jennifer L. Hall. Ordered by Judge Richard G. Andrews on 9/9/2021. Motions referred to Jennifer L. Hall.(nms)
|
| Filing 8 NOTICE of Appearance by Karen Elizabeth Keller on behalf of LGM Pharma, LLC (Keller, Karen) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 7 Local Counsel Letter sent. Notice of Compliance deadline set for 9/17/2021. (myr) (Main Document 7 replaced on 8/18/2021) (myr). |
| Filing 6 Record of case transferred in from District of Florida Southern; Case Number in Other District: 1:21-mc-22806. Copy of Docket Sheet and original file |
|
Filing 5
ORDER: It is ORDERED AND ADJUDGED that the Clerk of Court shall transfer this miscellaneous action and the Motion to Quash to the U.S. District Court for the District of Delaware, Case No. 20-cv-00755-RGA-JLH. This case shall be closed in this district. Closing Case. Signed by Judge Darrin P. Gayles on 8/17/2021. See attached document for full details. (scn) [Transferred from Florida Southern on 8/18/2021.]
|
| Filing 4 NOTICE by United Therapeutics Corporation Joint Notice of Filing Proposed Agreed Order Transferring LGM Motion to Quash. Attorney Kamal H Sleiman added to party United Therapeutics Corporation(pty:pla). (Attachments: #1 Exhibit 1 - Proposed Order) (Sleiman, Kamal) [Transferred from Florida Southern on 8/18/2021.] |
| Filing 3 NOTICE OF COURT PRACTICE. Unless otherwise specified by the Court, every motion shall be double-spaced in Times New Roman 12-point typeface. Multiple Plaintiffs or Defendants shall file joint motions with co-parties unless there are clear conflicts of position. If conflicts of position exist, parties shall explain the conflicts in their separate motions. Failure to comply with ANY of these procedures may result in the imposition of appropriate sanctions, including but not limited to, the striking of the motion or dismissal of this action. Signed by Judge Darrin P. Gayles (jsi) [Transferred from Florida Southern on 8/18/2021.] |
| Filing 2 Judge Assignment to Judge Darrin P. Gayles. (scn) [Transferred from Florida Southern on 8/18/2021.] |
| Filing 1 Petition/Motion (Complaint) RE: Subpoena to Quash from Another District and to transfer to District Court of Delaware and Incorporated Memorandum of Law. Filing fee $49.00 receipt number AFLSDC-14894637, filed by LGM Pharma, LLC. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5, #6 Exhibit 6, #7 Exhibit 7, #8 Exhibit 8, #9 Exhibit 9, #10 Civil Cover Sheet)(Barton, Ana) [Transferred from Florida Southern on 8/18/2021.] |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
